Alpha Wave Global, LP bought $9.6M of ANRO
owner at Alto Neuroscience, Inc.. 600,000 shares at an average of $16.00, traded Feb 6, 2024, filed Feb 8, 2024.
Score components
- +12Role10% owner
- +25Trade size$9.6M at market
- +3Relative to holdingsHoldings up 19%
- +10Price context0% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-24-001290, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2024 | CConversion Common Stockindirect: See footnotes | +1,962,995 | - | - | 1,962,995 | Feb 8, 2024 |
| Feb 6, 2024 | CConversion Common Stockindirect: See footnotes | +1,144,762 | - | - | 3,107,757 | Feb 8, 2024 |
| Feb 6, 2024 | POpen-market purchase Common Stockindirect: See footnotes | +600,000 | $16.00 | $9.6M | 3,707,757 | Feb 8, 2024 |
| Feb 6, 2024 | CConversion Series B Convertible Preferred Stock (Series B Preferred)derivativeindirect: See footnotes | -1,962,995 | $0.00 | $0 | 0 | Feb 8, 2024 |
| Feb 6, 2024 | CConversion Series C Convertible Preferred Stock (Series C Preferred)derivativeindirect: See footnotes | -1,144,763 | $0.00 | $0 | 0 | Feb 8, 2024 |
Related signals
Other insiders at Alto Neuroscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | Alto Neuroscience, Inc. | Nicholas Conrad Smith PRESIDENT AND CFO | $3.6M 134,886 shares | -100% | |
| 45Moderate | ANRObuy Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $191k 15,000 shares | +60% | |
| 47Moderate | ANRObuy Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $101k 6,150 shares | +30% | |
| 52Moderate | Alto Neuroscience, Inc. | Amit Etkin PRESIDENT AND CEO | $50k 3,125 shares | +0% | |
| 63Notable | Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $272k 17,000 shares | +217% | |
| 60Notable | Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $25k 1,563 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.